Novavax, Inc., A Biotechnology Company Dedicated To Developing And Commercializing Next-Generation Vaccines For Serious Infectious Diseases, Announced Positive Results From The Phase 1/2 Clinical Trial Of Its Covid-19-Influenza Combination (Cic) Vaccine Candidate. Data Demonstrated The Cic Vaccine'S Ability To Generate Immune Responses, Including Both Antibody And Polyfunctional Cd4+ T-Cell (Lymphocytes That Help Coordinate The Immune Response) Responses Against Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) And Homologous And Heterologous Influenza Strains. The Cic Combines Novavax' Covid-19 Vaccine (Nvx-Cov2373) And Its Quadrivalent Influenza Vaccine Candidate.The Cic Vaccine Formulations Demonstrated Induction Of Polyfunctional Cd4+ T-Cell Responses Against Both Sars-Cov-2 And Homologous And Heterologous Influenza Strains At Levels Comparable To Stand-Alone Nvx-Cov2373 And Quadrivalent Influenza Vaccine Candidate Reference Formulations. Nvx-Cov2373 Has Previously Been Shown To Induce Functional Sars-Cov-2
